Search

Your search keyword '"Ramos, Guilherme S."' showing total 8 results
Start Over Author "Ramos, Guilherme S."
8 results on '"Ramos, Guilherme S."'

3. Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

Author

Frézard, Frédéric, primary, Aguiar, Marta M. G., additional, Ferreira, Lucas A. M., additional, Ramos, Guilherme S., additional, Santos, Thais T., additional, Borges, Gabriel S. M., additional, Vallejos, Virgínia M. R., additional, and De Morais, Helane L. O., additional

Published
2022
Full Text
View/download PDF

5. Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes

Author

Ramos, Guilherme S., primary, Vallejos, Virgínia M. R., additional, Borges, Gabriel S. M., additional, Almeida, Raquel M., additional, Alves, Izabela M., additional, Aguiar, Marta M. G., additional, Fernandes, Christian, additional, Guimarães, Pedro P. G., additional, Fujiwara, Ricardo T., additional, Loiseau, Philippe M., additional, Ferreira, Lucas A. M., additional, and Frézard, Frédéric, additional

Published
2022
Full Text
View/download PDF

6. Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.

Author

Frézard, Frédéric, Aguiar, Marta M. G., Ferreira, Lucas A. M., Ramos, Guilherme S., Santos, Thais T., Borges, Gabriel S. M., Vallejos, Virgínia M. R., and De Morais, Helane L. O.

Subjects
AMPHOTERICIN B, LEISHMANIASIS, CUTANEOUS leishmaniasis, VISCERAL leishmaniasis, DRUG toxicity, DRUG efficacy
Abstract

The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient's immunological status, the clinical manifestation and the endemic region. Moreover, the need for parenteral administration, its side effects and high cost significantly limit its use in developing countries. This review reports the progress achieved thus far toward the understanding of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the development of more effective liposomal AmB formulations, including topical and oral liposome formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to guide future research and development of innovative liposomal formulations of AmB. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum

Author

dos Santos, Cristiano C. P., primary, Ramos, Guilherme S., additional, De Paula, Renata C., additional, Faria, Karen F., additional, Moreira, Paulo O. L., additional, Pereira, Ramon A., additional, Melo, Maria N., additional, Tafuri, Wagner L., additional, Demicheli, Cynthia, additional, Ribeiro, Raul R., additional, Azevedo, Erly G., additional, Do Monte-Neto, Rubens, additional, Da Silva, Sydnei M., additional, and Frézard, Frédéric, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results